Drug therapy.
D000661:Amphetamine / Q000627:therapeutic use; D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy; D002090:Butyrophenones / Q000627:therapeutic use; D002749:Chlorprothixene / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy; D005116:Extrapyramidal Tracts / Q000187:drug effects; D006213:Hallucinogens / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008094:Lithium / Q000627:therapeutic use; D008238:Lysergic Acid Diethylamide / Q000627:therapeutic use; D001523:Mental Disorders / Q000188:drug therapy*; D008722:Methods; D010640:Phenothiazines / Q000009:adverse effects / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D010919:Placebos; D011600:Psychopharmacology / Q000592:standards; D011613:Psychotherapy; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use
D000928:Antidepressive Agents; D002090:Butyrophenones; D006213:Hallucinogens; D006993:Hypnotics and Sedatives; D010640:Phenothiazines; D010879:Piperazines; D010919:Placebos; D014149:Tranquilizing Agents; D008238:Lysergic Acid Diethylamide; D008094:Lithium; D002749:Chlorprothixene; D000661:Amphetamine